Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 0.0 | BCD100322A002 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 0.5 | BCD100322A005 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 1.0 | BCD100322A009 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 2.0 | BCD100322A013 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 4.0 | BCD100322A017 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 8.0 | BCD100322A021 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 12.0 | BCD100322A025 | 0.33 | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | Lipid-depleted/compactin | 24.0 | BCD100322A029 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 0.0 | BCD100322A001 | 0.61 | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 0.5 | BCD100322A003 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 1.0 | BCD100322A007 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 2.0 | BCD100322A011 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 4.0 | BCD100322A015 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 8.0 | BCD100322A019 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 12.0 | BCD100322A023 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | C | 24.0 | BCD100322A027 | 0.56 | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100322A006 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100322A010 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100322A014 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100322A018 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100322A022 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100322A026 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100322A030 | 0.35 | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 0.5 | BCD100322A004 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 1.0 | BCD100322A008 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 2.0 | BCD100322A012 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 4.0 | BCD100322A016 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 8.0 | BCD100322A020 | - | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 12.0 | BCD100322A024 | 0.28 | pmol/sample |
| LMFA01030408 | 13,16,19-docosatrienoic acid | 25OH-Chol | 24.0 | BCD100322A028 | 1.63 | pmol/sample |